Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OnabotulinumtoxinA is a purified neurotoxic protein produced by the bacterium *Clostridium botulinum*. It is classified as a botulinum toxin type A product and acts as an acetylcholine release inhibitor and neuromuscular blocking agent. OnabotulinumtoxinA works by blocking the presynaptic release of acetylcholine at neuromuscular junctions, resulting in temporary muscle paralysis or relaxation. This mechanism underlies its use in treating various conditions involving muscle overactivity, such as cervical dystonia, spasticity, blepharospasm, and strabismus. It also inhibits cholinergic transmission to sweat glands for hyperhidrosis treatment and modulates pain pathways for chronic migraine prevention. Cosmetically, it reduces dynamic wrinkles by relaxing targeted facial muscles[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on onabotulinumtoxinA.